Adrenocortical carcinoma Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Adrenocortical carcinoma Pipeline Analysis report covers drugs of 11 companies currently in different phases of development. Adrenal cortical carcinoma (ACC) or Adrenocortical carcinoma is a rare disease which is caused by the cancerous growth in the adrenal cortex. Adrenal cortex is the outer layer of the adrenal glands and lie on the top of the kidneys. The adrenal cortex regulates the body metabolism and blood pressure via the production of hormones. There are two types of adrenocortical carcinoma namely functioning tumours and non-functioning tumours. The symptoms of the disease depend on the type of the hormones produced by the adrenal cortex.
The report provides Adrenocortical carcinoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Arbutus Biopharma, Trovagene, Infinity Pharmaceuticals, Inc. and Millendo Therapeutics, Inc among others.
By Molecule Type
By Route of Administration